Technology 126 of 266
Cell engineering
4 EIC Accelerator winners build on Cell engineering, 0% of the classified companies, in 1 sector and 1 industry.
4
Companies
1
Sectors
1
Industries
2
Countries
0%
Exits
0%
Show signs of scaling
Sectors
- Health4 (100%)
Industries
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Cell engineering
Show the numbers
| Companies | Cell engineering | |
|---|---|---|
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 1 | 1 |
| 2023 | 3 | 3 |
| 2024 | 0 | 0 |
What happened to them (4 of 4 checked)
- Active3 (75%)
- Exit0 (0%)
- Failed1 (25%)
- Other0 (0%)
Signs of scaling
- Scaling0 (0%)
- Not scaling1 (25%)
- Scaling unclear3 (75%)
All 4 companies using Cell engineering
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| ErVaccine Technologies | OVACellDevelopment of a cell immunotherapy targeting non-conventional tumor antigens in ovarian cancer | Biopharmaceuticals | France | June 2023 | Blended finance | Active | Deep dive |
| NEOGAP Therapeutics AB | NEOpTTLInnovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement | Biopharmaceuticals | Sweden | March 2023 | Blended finance | Active | Deep dive |
| SMART IMMUNE | Smart ProTcellSmart Immune ProTcell: first-in-class allogeneic thymus empowered T cell therapy platform for fast and durable immune system reconstitution | Biopharmaceuticals | France | January 2023 | Blended finance | Insolvent | Deep dive |
| Elicera Therapeutics AB | CD20CARNAPTiTANK: a nuniversal technology to boost the efficacy of CAR T cell therapies by inducing dual mode-of-actio | Biopharmaceuticals | Sweden | March 2022 | Grant only | Active | Deep dive |